Completed PHASE3 INTERVENTIONAL 4-arm NCT00028574

Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Management of Hot Flashes in Men

Sponsor: Alliance for Clinical Trials in Oncology

Updated 7 times since 2017 Last updated: Jun 27, 2016 Started: Dec 31, 2001 Primary completion: Dec 31, 2006 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00028574, this PHASE3 trial focuses on Hot Flashes and Prostate Cancer and remains completed. Sponsored by Alliance for Clinical Trials in Oncology, it has been updated 7 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adrian, United States , Albert Lea, United States , Alexandria, United States , Ames, United States , Anderson, United States , Ann Arbor, United States , Aurora, United States , Bettendorf, United States , Billings, United States , Bismarck, United States and 96 more locations